A Phase 1, Dose Escalation Study of Intravenous TK216 in
Patients with Relapsed or Refractory Ewing Sarcoma - Expansion Cohort Segment Only
This study is being done to test the good and bad effects of TK216 in patients aged 10-100 years with relapsed or refractory Ewing sarcoma (ES) (includes patients with Ewing sarcoma family of tumors-ESFT).
Ewing sarcoma (ES), Ewing sarcoma family of tumors-ESFT
1. Patients, both male and female, aged 10 years or older
2. Have confirmed diagnosis of Ewing sarcoma (ES), including patients with Ewing sarcoma family of tumors-ESFT
3. Adequate organ function
4. Other criteria apply
10 - 100
Healthy Volunteers Needed
Duration of Participation
Knight Clinical Trials Information Line
Oncternal Therapeutics, Inc.